These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2958829)

  • 21. Dopaminergic innervation of the human striatum in Parkinson's disease.
    Papapetropoulos S; Basel M; Mash DC
    Mov Disord; 2007 Jan; 22(2):286-8. PubMed ID: 17083095
    [No Abstract]   [Full Text] [Related]  

  • 22. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
    Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pathochemical perspectives of Parkinson's disease. An attempt at a neurochemical definition.
    Hornykiewicz O
    Funct Neurol; 1988; 3(4):379-91. PubMed ID: 3072274
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. L-dopa in Parkinson's disease.
    Horstink MW; van de Vlasakker CJ
    Neurology; 1991 Oct; 41(10):1709. PubMed ID: 1922837
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
    Narabayashi H
    No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
    [No Abstract]   [Full Text] [Related]  

  • 27. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal dopamine loss and discriminative sensory dysfunction in Parkinson's disease.
    Lyoo CH; Ryu YH; Lee MJ; Lee MS
    Acta Neurol Scand; 2012 Nov; 126(5):344-9. PubMed ID: 22380639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease.
    Sage JI; Mark MH
    Neurology; 1992 Jan; 42(1 Suppl 1):23-8; discussion 57-60. PubMed ID: 1347908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seasonality of striatal dopamine synthesis capacity in Parkinson's disease.
    Kaasinen V; Jokinen P; Joutsa J; Eskola O; Rinne JO
    Neurosci Lett; 2012 Nov; 530(1):80-4. PubMed ID: 23041046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dopa-responsive, nonprogressive juvenile parkinsonism: report of a case.
    Rajput A; Kishore A; Snow B; Bolton CF; Rajput AH
    Mov Disord; 1997 May; 12(3):453-6. PubMed ID: 9159748
    [No Abstract]   [Full Text] [Related]  

  • 32. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 33. Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.
    Constantinidis J; Siegfried J; Frigyesi TL; Tissot R
    J Neural Transm; 1974; 35(1):13-22. PubMed ID: 4824675
    [No Abstract]   [Full Text] [Related]  

  • 34. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurochemistry of Parkinson's disease: relation between striatal and limbic dopamine.
    Price KS; Farley IJ; Hornykiewicz O
    Adv Biochem Psychopharmacol; 1978; 19():293-300. PubMed ID: 696462
    [No Abstract]   [Full Text] [Related]  

  • 37. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease.
    de la Fuente-Fernández R; Ruth TJ; Sossi V; Schulzer M; Calne DB; Stoessl AJ
    Science; 2001 Aug; 293(5532):1164-6. PubMed ID: 11498597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amine precursors in neurologic disorders and the psychoses.
    Klawans H
    Res Publ Assoc Res Nerv Ment Dis; 1975; 54():259-76. PubMed ID: 130667
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased dopamine in the retinas of patients with Parkinson's disease.
    Harnois C; Di Paolo T
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.